Quick Answer
ZyVersa Therapeutics, Inc. reported Net Income Loss of -$24.95 million for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -165.1% in Net Income Loss from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$1.1 thousand | Q2 2021: -$789.00 | Q3 2021: -$174.00 | Q1 2022: -$720.0 thousand | Q2 2022: -$393.6 thousand | Q3 2022: -$679.1 thousand | Q1 2023: -$3.54 million | Q2 2023: -$78.51 million | Q3 2023: -$2.90 million | Q1 2024: -$2.83 million | Q2 2024: -$2.76 million | Q3 2024: -$2.40 million | Q1 2025: -$2.26 million | Q2 2025: -$2.21 million | Q3 2025: -$19.81 million.
- Over the full 5 years of available data (2022 to 2025), ZyVersa Therapeutics, Inc.'s Net Income Loss has declined by 77.6%.
- Historical annual values: Fiscal year 2025: -$24.95 million | Fiscal year 2024: -$9.41 million | Fiscal year 2023: -$98.30 million | Fiscal year 2022: -$75.0 thousand | Fiscal year 2022: -$14.05 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: